Log In
BCIQ
Print this Print this
 

Anti-HIF2 siRNA DPCs (ARC-HIF2)

  Manage Alerts
Collapse Summary General Information
Company Arrowhead Pharmaceuticals Inc.
DescriptionRNA interference targeting factor hypoxia-inducible factor 2α (HIF-2α) delivered extrahepatically using Dynamic Polyconjugate technology
Molecular Target
Mechanism of Action 
Therapeutic ModalityNucleic acid: Linear RNA: siRNA
Latest Stage of DevelopmentPreclinical
Standard IndicationRenal cancer
Indication DetailsTreat clear cell renal cell carcinoma (ccRCC)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today